Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 14NIH 4INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 130Lymphoma, Large B-Cell, Diffuse 101Lymphoma, Follicular 90Leukemia, Lymphocytic, Chronic, B-Cell 82Lymphoma 63Lymphoma, B-Cell 43Recurrence 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 23Neoplasms 22Leukemia 10Hematologic Diseases 10Lymphatic Diseases 8Multiple Myeloma 7Immunoproliferative Disorders 6Hematologic Neoplasms 6Waldenstrom Macroglobulinemia 5Lymphoproliferative Disorders 5Leukemia, B-Cell 5Arthritis, Rheumatoid 5Hodgkin Disease 4Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Immune System Diseases 3Dendritic Cell Sarcoma, Interdigitating 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2

Interventions

Rituximab 3Brentuximab Vedotin 2venetoclax 1veltuzumab 1pirtobrutinib 1ontuxizumab 1iratumumab 1exatecan 1durvalumab 1Zidovudine 1Vincristine 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Prednisone 1Prednisolone 1Oxaliplatin 1Mitoxantrone 1Mannose-Binding Lectin 1Lenalidomide 1Gemcitabine 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bendamustine Hydrochloride 1Antibodies, Monoclonal 1Adrenal Cortex Hormones 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Dendritic Cell Sarcoma, Interdigitating × Rituximab × Clear all
NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT01118845 2013-07-04

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

SymBio Pharmaceuticals

Phase 2 Completed
63 enrolled 46 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡